摘要:
Die Erfindung betrifft rekombinante VSV-Viren und virale Vektoren, welche ein Glykoprotein GP des lymphozytären Choriomeningitisvirus (LCMV) anstelle des G-Proteins des VSV enthalten, Virusproduzentenzellen, welche mit LCMV-GP pseudotypisierte VSV-Virionen produzieren, sowie die Verwendung genannter Vektoren und Zellen zur Therapie solider Tumore, insbesondere Hirntumore.
摘要:
The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.
摘要:
The invention relates to arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (improved) tumor-regression properties.
摘要:
The invention relates to recombinant VSV viruses and viral vectors which produce a glycoprotein GP of the lymphocytic choriomeningitis virus (LCMV) instead of the G protein of the VSV, to virus-producing cells which produce LCMV-GP-pseudotyped VSV virions, and to the use of said vectors and cells in the therapy of solid tumors, especially brain tumors.